Literature DB >> 16554262

Therapy of X-linked adrenoleukodystrophy.

Hugo W Moser1.   

Abstract

Current therapies for X-linked adrenoleukodystrophy (X-ALD) include replacement therapy with adrenal steroids, which is mandatory for all patients with impaired adrenal function but does not alter neurological progression significantly; dietary therapy with "Lorenzo's Oil," which appears to have a preventive effect in asymptomatic boys whose brain MRI is normal; and hematopoietic stem cell transplantation in patients in the early stage of the cerebral inflammatory phenotype. Application of these interventions requires careful assessment of the patients' phenotype, which often changes over time. Family screening provides important opportunities for disease prevention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16554262      PMCID: PMC3593437          DOI: 10.1016/j.nurx.2006.01.004

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  64 in total

1.  Adrenoleukodystrophy: the most frequent genetic cause of Addison's disease.

Authors:  Patrick Aubourg; Jean-Louis Chaussain
Journal:  Horm Res       Date:  2003

2.  Clinical and electrophysiological improvement of adrenomyeloneuropathy with steroid treatment.

Authors:  L X Zhang; R Bakshi; E Fine; H W Moser
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

3.  Adrenoleukodystrophy. A clinical and pathological study of 17 cases.

Authors:  H H Schaumburg; J M Powers; C S Raine; K Suzuki; E P Richardson
Journal:  Arch Neurol       Date:  1975-09

4.  Spectroscopic evidence of cerebral axonopathy in patients with "pure" adrenomyeloneuropathy.

Authors:  P Dubey; A Fatemi; P B Barker; M Degaonkar; M Troeger; K Zackowski; A Bastian; S A Smith; M G Pomper; H W Moser; G V Raymond
Journal:  Neurology       Date:  2005-01-25       Impact factor: 9.910

5.  MRI and proton MRSI in women heterozygous for X-linked adrenoleukodystrophy.

Authors:  A Fatemi; P B Barker; A M Uluğ; L M Nagae-Poetscher; N J Beauchamp; A B Moser; G V Raymond; H W Moser; S Naidu
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

6.  Biochemical effect of intravenous arginine butyrate in X-linked adrenoleukodystrophy.

Authors:  Margaret M McGovern; Melissa P Wasserstein; Alan Aron; Susan P Perrine
Journal:  J Pediatr       Date:  2003-06       Impact factor: 4.406

7.  Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999.

Authors:  Charles Peters; Lawrence R Charnas; Ye Tan; Richard S Ziegler; Elsa G Shapiro; Todd DeFor; Satkiran S Grewal; Paul J Orchard; Susan L Abel; Anne I Goldman; Norma K C Ramsay; Kathryn E Dusenbery; Daniel J Loes; Lawrence A Lockman; Shunichi Kato; Patrick R Aubourg; Hugo W Moser; William Krivit
Journal:  Blood       Date:  2004-04-08       Impact factor: 22.113

8.  Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy.

Authors:  D J Loes; A Fatemi; E R Melhem; N Gupte; L Bezman; H W Moser; G V Raymond
Journal:  Neurology       Date:  2003-08-12       Impact factor: 9.910

9.  Correlation of very long chain fatty acid accumulation and inflammatory disease progression in childhood X-ALD: implications for potential therapies.

Authors:  Ajaib Singh Paintlia; Anne Genevieve Gilg; Mushfiquddin Khan; Avtar Kaur Singh; Ernest Barbosa; Inderjit Singh
Journal:  Neurobiol Dis       Date:  2003-12       Impact factor: 5.996

10.  Thyroid hormone induction of the adrenoleukodystrophy-related gene (ABCD2).

Authors:  Stéphane Fourcade; Stéphane Savary; Catherine Gondcaille; Johannes Berger; Angela Netik; Françoise Cadepond; Martine El Etr; Brunhilde Molzer; Maurice Bugaut
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

View more
  18 in total

1.  Pediatric neurotherapy.

Authors:  Leon S Dure; Faye Silverstein
Journal:  NeuroRx       Date:  2012-09-05

Review 2.  Oxidative Stress in Patients with X-Linked Adrenoleukodystrophy.

Authors:  Marion Deon; Desirèe P Marchetti; Bruna Donida; Moacir Wajner; Carmen Vargas
Journal:  Cell Mol Neurobiol       Date:  2015-07-14       Impact factor: 5.046

3.  X-linked adrenoleukodystrophy presenting as Addison's disease.

Authors:  Bernhard Kaspar Morell; Jens Teichler; Kemal Budak; Jörg Vollenweider; Vojtech Pavlicek
Journal:  BMJ Case Rep       Date:  2010-05-13

4.  HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes.

Authors:  Jaspreet Singh; Mushfiquddin Khan; Inderjit Singh
Journal:  J Lipid Res       Date:  2011-09-04       Impact factor: 5.922

5.  Hexacosanoic and docosanoic acids plasma levels in patients with cerebral childhood and asymptomatic X-linked adrenoleukodystrophy: Lorenzo's oil effect.

Authors:  Marion Deon; Mariana Pires Garcia; Angela Sitta; Alethéa G Barschak; Daniella M Coelho; Graziela O Schimit; Maiara Pigatto; Laura B Jardim; Moacir Wajner; Roberto Giugliani; Carmen R Vargas
Journal:  Metab Brain Dis       Date:  2007-11-17       Impact factor: 3.584

6.  Yoga as Therapy for Neurodegenerative Disorders: A Case Report of Therapeutic Yoga for Adrenomyeloneuropathy.

Authors:  Charlene Marie Muhammad; Steffany Haaz Moonaz
Journal:  Integr Med (Encinitas)       Date:  2014-06

7.  Newborn screening for X-linked adrenoleukodystrophy: further evidence high throughput screening is feasible.

Authors:  Christiane Theda; Katy Gibbons; Todd E Defor; Pamela K Donohue; W Christopher Golden; Antonie D Kline; Fizza Gulamali-Majid; Susan R Panny; Walter C Hubbard; Richard O Jones; Anita K Liu; Ann B Moser; Gerald V Raymond
Journal:  Mol Genet Metab       Date:  2013-11-09       Impact factor: 4.797

8.  Silencing of Abcd1 and Abcd2 genes sensitizes astrocytes for inflammation: implication for X-adrenoleukodystrophy.

Authors:  Jaspreet Singh; Mushfiquddin Khan; Inderjit Singh
Journal:  J Lipid Res       Date:  2008-08-21       Impact factor: 5.922

9.  MicroRNA Profiling Identifies miR-196a as Differentially Expressed in Childhood Adrenoleukodystrophy and Adult Adrenomyeloneuropathy.

Authors:  Navjot Shah; Inderjit Singh
Journal:  Mol Neurobiol       Date:  2016-02-03       Impact factor: 5.590

10.  Intravenous immunoglobulin treatment in a patient with adrenomyeloneuropathy.

Authors:  Aia Elise Jønch; Else Rubæk Danielsen; Carsten Thomsen; Per Meden; Kirsten Svenstrup; Jørgen Erik Nielsen
Journal:  BMC Neurol       Date:  2012-09-26       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.